Skip to content

Study · Not a test of the peptide alone · 2022

4 results

Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review.

Mantovani A, Byrne CD, Targher G

The lancet. Gastroenterology & hepatology12 Jan 2022Cited by 195 (Europe PMC)

PMID35030323 (opens in a new tab)DOI10.1016/s2468-1253(21)00261-2 (opens in a new tab)PepBankPUB-35030323
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 01HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In a systematic review of trials in adults with NAFLD, pooled GLP-1 receptor agonists (mostly liraglutide and semaglutide) improved individual histological features of NASH.

    In plain wordsIn a review of trials in fatty liver disease, GLP-1 drugs as a group improved liver tissue changes.

    Peptide
    Liraglutide
    Outcome
    DecreaseHistological features of NASH (steatosis, ballooning, lobular inflammation), GLP-1R agonists pooled
    Study

    n: not reported in source

    Outcome group
    Liver fat and liver function · Liver

    Source sentences

    Summary
    Pioglitazone, lanifibranor, and GLP1-R agonists (mostly liraglutide and semaglutide) improved individual histological features of NASH (ie, steatosis, ballooning, lobular inflammation) or achieved resolution of NASH without worsening of fibrosis.
    1 context sentence
    Summary · context
    We did a systematic review of randomised controlled trials examining the efficacy of PPAR agonists, GLP-1R agonists, or SGLT2 inhibitors for specifically treating NAFLD in adults with or without type 2 diabetes.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In a systematic review of trials in adults with NAFLD, pooled GLP-1 receptor agonists (mostly liraglutide and semaglutide) improved individual histological features of NASH.

    In plain wordsIn a review of trials in fatty liver disease, GLP-1 drugs as a group improved liver tissue changes.

    Peptide
    Semaglutide
    Outcome
    DecreaseHistological features of NASH (steatosis, ballooning, lobular inflammation), GLP-1R agonists pooled
    Study

    n: not reported in source

    Outcome group
    Liver fat and liver function · Liver

    Source sentences

    Summary
    Pioglitazone, lanifibranor, and GLP1-R agonists (mostly liraglutide and semaglutide) improved individual histological features of NASH (ie, steatosis, ballooning, lobular inflammation) or achieved resolution of NASH without worsening of fibrosis.
    1 context sentence
    Summary · context
    We did a systematic review of randomised controlled trials examining the efficacy of PPAR agonists, GLP-1R agonists, or SGLT2 inhibitors for specifically treating NAFLD in adults with or without type 2 diabetes.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  3. 03HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In a systematic review of trials in adults with NAFLD, pooled GLP-1 receptor agonists (mostly liraglutide and semaglutide) achieved resolution of NASH without worsening of fibrosis.

    In plain wordsIn a review of trials in fatty liver disease, GLP-1 drugs as a group cleared NASH without worsening scarring.

    Peptide
    Liraglutide
    Outcome
    IncreaseResolution of NASH without worsening of fibrosis, GLP-1R agonists pooled
    Study

    n: not reported in source

    Outcome group
    Liver fat and liver function · Liver

    Source sentences

    Summary
    Pioglitazone, lanifibranor, and GLP1-R agonists (mostly liraglutide and semaglutide) improved individual histological features of NASH (ie, steatosis, ballooning, lobular inflammation) or achieved resolution of NASH without worsening of fibrosis.
    1 context sentence
    Summary · context
    We did a systematic review of randomised controlled trials examining the efficacy of PPAR agonists, GLP-1R agonists, or SGLT2 inhibitors for specifically treating NAFLD in adults with or without type 2 diabetes.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  4. 04HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In a systematic review of trials in adults with NAFLD, pooled GLP-1 receptor agonists (mostly liraglutide and semaglutide) achieved resolution of NASH without worsening of fibrosis.

    In plain wordsIn a review of trials in fatty liver disease, GLP-1 drugs as a group cleared NASH without worsening scarring.

    Peptide
    Semaglutide
    Outcome
    IncreaseResolution of NASH without worsening of fibrosis, GLP-1R agonists pooled
    Study

    n: not reported in source

    Outcome group
    Liver fat and liver function · Liver

    Source sentences

    Summary
    Pioglitazone, lanifibranor, and GLP1-R agonists (mostly liraglutide and semaglutide) improved individual histological features of NASH (ie, steatosis, ballooning, lobular inflammation) or achieved resolution of NASH without worsening of fibrosis.
    1 context sentence
    Summary · context
    We did a systematic review of randomised controlled trials examining the efficacy of PPAR agonists, GLP-1R agonists, or SGLT2 inhibitors for specifically treating NAFLD in adults with or without type 2 diabetes.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.